Catalyst Biosciences CFO Clinton Musil resigns; controller Seline Miller named interim CFO

GYRE THERAPEUTICS, INC.

Clinton Musil resigns as CFO effective Oct 29, 2021 for personal reasons; will provide consulting services.
Seline Miller promoted to SVP Finance and named interim CFO and principal accounting officer.
Miller's base salary increased to $300k (from $250k) and bonus target raised to 30% (from 25%).
Company initiates search for a permanent CFO.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Clinton Musil

Chief Financial Officer

GYRE · GYRE THERAPEUTICS, INC.

Effective: 2021-10-29
Successor: Seline Miller
Filed: October 13, 2021, 7:59 PM ET

On October 7, 2021, Clinton Musil, Chief Financial Officer of Catalyst Biosciences, Inc. (the “Company”), notified the Company of his decision to resign for personal reasons.

Role change (interim)

Seline Miller

Senior Vice President, Finance and interim Chief Financial Officer

GYRE · GYRE THERAPEUTICS, INC.

Filed: October 13, 2021, 7:59 PM ET

Seline Miller, the Company’s Controller, was promoted to Senior Vice President, Finance and will serve as the Company’s interim Chief Financial Officer and interim Principal Accounting Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Clinton Musil resigned as Chief Financial Officer at GYRE THERAPEUTICS, INC..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On October 7, 2021, Clinton Musil, Chief Financial Officer of Catalyst Biosciences, Inc. (the “Company”), notified the Company of his decision to resign for personal reasons.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Seline Miller changed role as Senior Vice President, Finance and interim Chief Financial Officer at GYRE THERAPEUTICS, INC..

Action: promoted
Role: Senior Vice President, Finance and interim Chief Financial Officer

Exact text from the filing

Seline Miller, the Company’s Controller, was promoted to Senior Vice President, Finance and will serve as the Company’s interim Chief Financial Officer and interim Principal Accounting Officer.

View on SEC.gov

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-21-297901

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.